On Monday, ARS Pharmaceuticals earned an upgrade to its Relative Strength (RS) Rating, from 89 to 92.
Looking For The Best Stocks To Buy And Watch? Start Here
This unique rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an 80 or higher RS Rating in the early stages of their moves.
While ARS Pharmaceuticals is not near an ideal entry right now, see if it manages to form and break out from a proper consolidation.
ARS Pharmaceuticals showed 0% EPS growth last quarter, while sales growth came in at 4,900%.
ARS Pharmaceuticals earns the No. 77 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and TG Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
